{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:54:39Z","timestamp":1791982479294,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"T\u00dcB\u0130TAK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral infection caused by Crimean-Congo hemorrhagic fever virus (CCHFV). Serological screening of CCHF is important and current ELISA use antigens prepared from virus which is expensive due to requirement of high bio-containment facilities. In this study, we aimed to develop a new recombinant ELISA. For this purpose, CCHFV genome were expressed as 13 proteins in <jats:italic>E. coli<\/jats:italic> and among them abundantly purified recombinant Nucleocapsid protein (rNP) and Mucin-like variable domain (rMLD) were used as antigen in ELISA (Rec-ELISA). Rec-ELISA using rNP, rMLD and a combination of both (rNP\/rMLD) were probed with acute (n\u2009=\u200964; collected between days 1 and 7 after onset of symptoms), convalescent (n\u2009=\u200935; collected 8\u00a0days after onset of symptoms), consecutive sera (n\u2009=\u200925) of confirmed CCHF cases and control sera (n\u2009=\u200943). The sensitivity and specificity of Rec-ELISA using rNP\/rMLD were 73% and 98% in acute cases and 97% and 98% in convalescent cases. The median interquartile absorbance value to discriminate the acute and convalescent phases of CCHF was significantly higher with ELISA using rNP\/rMLD (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) compared to rNP (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05) and rMLD (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). These results indicate that the Rec-ELISA using rNP\/rMLD may be very useful to diagnose convalescent CCHF cases especially in field studies.<\/jats:p>","DOI":"10.1038\/s41598-021-85323-1","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T11:03:41Z","timestamp":1615806221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of a novel recombinant ELISA for the detection of Crimean-Congo hemorrhagic fever virus IgG antibodies"],"prefix":"10.1038","volume":"11","author":[{"given":"Sultan","family":"G\u00fclce-\u0130z","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazif","family":"Elald\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra Atalay","family":"\u015eahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Karakavuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayt\u00fcl","family":"G\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem \u00d6rs","family":"Kumo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysu De\u011firmenci","family":"D\u00f6\u015fkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Y\u00fcksel","family":"G\u00fcr\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"\u00d6zdarendeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Louis","family":"Felgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"D\u00f6\u015fkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"85323_CR1","first-page":"S1","volume":"1","author":"N Elaldi","year":"2014","unstructured":"Elaldi, N. & Kaya, S. Crimean-Congo Hemorrhagic fever. J. Microbiol. Infect. Dis. 1, S1\u2013S9 (2014).","journal-title":"J. Microbiol. Infect. Dis."},{"key":"85323_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","volume":"100","author":"DA Bente","year":"2013","unstructured":"Bente, D. A. et al. Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome an genetic diversity. Antiviral. Res. 100, 159\u2013189 (2013).","journal-title":"Antiviral. Res."},{"issue":"387","key":"85323_CR3","first-page":"e1","volume":"22","author":"H Leblebicioglu","year":"2016","unstructured":"Leblebicioglu, H. et al. Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002\u20132014: A multicentre retrospective cross-sectional study. Clin. Microbiol. Infect. 22(387), e1-387.e4 (2016).","journal-title":"Clin. Microbiol. Infect."},{"key":"85323_CR4","doi-asserted-by":"publisher","first-page":"E953","DOI":"10.3390\/v11100953","volume":"11","author":"CEM Gruber","year":"2019","unstructured":"Gruber, C. E. M. et al. Geographical variability affects CCHFV detection by RT-PCR: A tool for in-silico evaluation of molecular assays. Viruses 11, E953 (2019).","journal-title":"Viruses"},{"key":"85323_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.antiviral.2016.09.004","volume":"134","author":"I Schuster","year":"2016","unstructured":"Schuster, I. et al. A competitive ELISA for species-independent detection of Crimean-Congo hemorrhagic fever virus specific antibodies. Antiviral. Res. 134, 161\u2013166 (2016).","journal-title":"Antiviral. Res."},{"key":"85323_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3181\/00379727-131-33847","volume":"131","author":"J Casals","year":"1969","unstructured":"Casals, J. Antigenic similarity between the virus causing Crimean hemorrhagic fever and Congo virus. Proc. Soc. Exp. Biol. Med. 131, 233\u2013236 (1969).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"85323_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ijid.2008.07.021","volume":"13","author":"GR Yilmaz","year":"2009","unstructured":"Yilmaz, G. R. et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002\u20132007. Int. J. Infect. Dis. 13, 380\u2013386 (2009).","journal-title":"Int. J. Infect. Dis."},{"key":"85323_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3201\/eid1503.080687","volume":"15","author":"T Gunes","year":"2009","unstructured":"Gunes, T. et al. Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey. Emerg. Infect. Dis. 15, 461\u2013464 (2009).","journal-title":"Emerg. Infect. Dis."},{"key":"85323_CR9","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/j.ijid.2009.02.011","volume":"13","author":"B Ertugrul","year":"2009","unstructured":"Ertugrul, B. et al. An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. Int. J. Infect. Dis. 13, e431-436 (2009).","journal-title":"Int. J. Infect. Dis."},{"key":"85323_CR10","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1099\/vir.0.035105-0","volume":"92","author":"CT Walter","year":"2011","unstructured":"Walter, C. T. & Barr, J. N. Recent advances in the molecular and cellular biology of bunyaviruses. Gen. Virol. 92, 2467\u20132484 (2011).","journal-title":"Gen. Virol."},{"key":"85323_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1473-3099(06)70435-2","volume":"6","author":"O Erg\u00f6n\u00fcl","year":"2006","unstructured":"Erg\u00f6n\u00fcl, O. Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. 6, 203\u2013214 (2006).","journal-title":"Lancet Infect. Dis."},{"key":"85323_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jviromet.2011.11.020","volume":"179","author":"SD Dowall","year":"2012","unstructured":"Dowall, S. D., Richards, K. S., Graham, V. A., Chamberlain, J. & Hewson, R. Development of an indirect ELISA method for the parallel measurement of IgG and IgM antibodies against Crimean-Congo haemorrhagic fever (CCHF) virus using recombinant nucleoprotein as antigen. J. Virol. Methods. 179, 335\u2013341 (2012).","journal-title":"J. Virol. Methods."},{"key":"85323_CR13","doi-asserted-by":"publisher","first-page":"e108419","DOI":"10.1371\/journal.pone.0108419","volume":"9","author":"D Liu","year":"2014","unstructured":"Liu, D. et al. Fine epitope mapping of the central immunodominant region of nucleoprotein from Crimean-Congo hemorrhagic fever virus (CCHFV). PLoS\u00a0One 9, e108419 (2014).","journal-title":"PLoS\u00a0One"},{"key":"85323_CR14","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1128\/JCM.40.5.1587-1591.2002","volume":"40","author":"M Saijo","year":"2002","unstructured":"Saijo, M. et al. Recombinant nucleoprotein-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Crimean-Congo hemorrhagic fever virus. J. Clin. Microbiol. 40, 1587\u20131591 (2002).","journal-title":"J. Clin. Microbiol."},{"key":"85323_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/jmv.20270","volume":"75","author":"M Saijo","year":"2005","unstructured":"Saijo, M. et al. Recombinant nucleoprotein-based serological diagnosis of Crimean-Congo hemorrhagic fever virus infections. J. Med. Virol. 75, 295\u2013299 (2005).","journal-title":"J. Med. Virol."},{"key":"85323_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jviromet.2011.09.023","volume":"179","author":"RR Samudzi","year":"2012","unstructured":"Samudzi, R. R., Leman, P. A., Paweska, J. T., Swanepoel, R. & Burt, F. J. Bacterial expression of Crimean-Congo hemorrhagic fever virus nucleoprotein and its evaluation as a diagnostic reagent in an indirect ELISA. J. Virol. Methods 179, 70\u201376 (2012).","journal-title":"J. Virol. Methods"},{"key":"85323_CR17","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1017\/S0950268813002987","volume":"142","author":"A Rangunwala","year":"2014","unstructured":"Rangunwala, A., Samudzi, R. R. & Burt, F. J. Detection of IgG antibody against Crimean-Congo haemorrhagic fever virus using ELISA with recombinant nucleoprotein antigens from genetically diverse strains. Epidemiol. Infect. 142, 2147\u20132154 (2014).","journal-title":"Epidemiol. Infect."},{"key":"85323_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.antiviral.2018.01.006","volume":"151","author":"MA Sas","year":"2018","unstructured":"Sas, M. A. et al. A novel double-antigen sandwich ELISA for the species-independent detection of Crimean-Congo hemorrhagic fever virus-specific antibodies. Antiviral Res. 151, 24\u201326 (2018).","journal-title":"Antiviral Res."},{"key":"85323_CR19","doi-asserted-by":"publisher","first-page":"e0006366","DOI":"10.1371\/journal.pntd.0006366","volume":"12","author":"P Emmerich","year":"2018","unstructured":"Emmerich, P. et al. Sensitive and specific detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV)-Specific IgM and IgG antibodies in human sera using recombinant CCHFV nucleoprotein as antigen in \u03bc-capture and IgG immune complex (IC) ELISA tests. PLoS Negl. Trop. Dis. 12, e0006366 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"85323_CR20","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3389\/fmicb.2019.01822","volume":"10","author":"N Shrivastava","year":"2019","unstructured":"Shrivastava, N. et al. Development of multispecies recombinant nucleoprotein-based indirect ELISA for high-throughput screening of Crimean-Congo hemorrhagic fever virus-specific antibodies. Front. Microbiol. 10, 1822 (2019).","journal-title":"Front. Microbiol."},{"key":"85323_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jviromet.2016.07.025","volume":"236","author":"R Atkinson","year":"2016","unstructured":"Atkinson, R., Burt, F., Rybicki, E. P. & Meyers, A. E. Plant-produced Crimean-Congo haemorrhagic fever virus nucleoprotein for use in indirect ELISA. J. Virol. Methods 236, 170\u2013177 (2016).","journal-title":"J. Virol. Methods"},{"key":"85323_CR22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1099\/vir.0.071332-0","volume":"96","author":"JM Levingston Macleod","year":"2015","unstructured":"Levingston Macleod, J. M., Marmor, H., Garc\u00eda-Sastre, A. & Frias-Staheli, N. Mapping of the interaction domains of the Crimean-Congo hemorrhagic fever virus nucleocapsid protein. J. Gen. Virol. 96, 524\u2013537 (2015).","journal-title":"J. Gen. Virol."},{"key":"85323_CR23","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.1128\/JVI.76.14.7263-7275.2002","volume":"76","author":"AJ Sanchez","year":"2002","unstructured":"Sanchez, A. J., Vincent, M. J. & Nichol, S. T. Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J. Virol. 76, 7263\u20137275 (2002).","journal-title":"J. Virol."},{"key":"85323_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1128\/JVI.80.1.514-525.2006","volume":"80","author":"AJ Sanchez","year":"2006","unstructured":"Sanchez, A. J., Vincent, M. J., Erickson, B. R. & Nichol, S. T. Crimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J. Virol. 80, 514\u2013525 (2006).","journal-title":"J. Virol."},{"key":"85323_CR25","doi-asserted-by":"publisher","first-page":"e1004879","DOI":"10.1371\/journal.ppat.1004879","volume":"11","author":"\u00c9 Bergeron","year":"2015","unstructured":"Bergeron, \u00c9. et al. Recovery of recombinant Crimean Congo hemorrhagic fever virus reveals a function for non-structural glycoproteins cleavage by furin. PLoS Pathog. 11, e1004879 (2015).","journal-title":"PLoS Pathog."},{"key":"85323_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1128\/JVI.01859-09","volume":"84","author":"E Bergeron","year":"2010","unstructured":"Bergeron, E., Albari\u00f1o, C. G., Khristova, M. L. & Nichol, S. T. Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor protease activity is dispensable for virus RNA polymerase function. J. Virol. 84, 216\u2013226 (2010).","journal-title":"J. Virol."},{"key":"85323_CR27","doi-asserted-by":"publisher","first-page":"1800093","DOI":"10.2807\/1560-7917.ES.2019.24.5.1800093","volume":"24","author":"B Bartolini","year":"2019","unstructured":"Bartolini, B. et al. Laboratory management of Crimean-Congo haemorrhagic fever virus infections: Perspectives from two European networks. Euro Surveill. 24, 1800093 (2019).","journal-title":"Euro Surveill."},{"key":"85323_CR28","unstructured":"WHO. WHO R&D Blueprint: Priority Diagnostics for CCHF Use Scenarios and Target Product Profiles. http:\/\/www.searo.who.int\/docs\/default-source\/blue-print\/call-for-comments\/who-cchf-tpp-dx-draft-v1-0.pdf?sfvrsn=a5b8580_2 (2019)."},{"key":"85323_CR29","unstructured":"Anonymous. Crimean-Congo Hemorrhagic Fever (CCHF). Center for Disease Control and Prevention (CDC). https:\/\/www.cdc.gov\/vhf\/crimean-congo\/diagnosis\/index.html (2020)."},{"key":"85323_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/1471-2334-14-416","volume":"14","author":"S Kaya","year":"2014","unstructured":"Kaya, S. et al. Sequential determination of serum viral titers, virus-specific IgG antibodies, and TNF-\u03b1, IL-6, IL-10, and IFN-\u03b3 levels in patients with Crimean-Congo hemorrhagic fever. BMC Infect. Dis. 14, 416 (2014).","journal-title":"BMC Infect. Dis."},{"key":"85323_CR31","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3201\/eid1311.070222","volume":"13","author":"D Duh","year":"2007","unstructured":"Duh, D. et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg. Infect. Dis. 13, 1769\u20131772 (2007).","journal-title":"Emerg. Infect. Dis."},{"key":"85323_CR32","doi-asserted-by":"publisher","first-page":"e001114","DOI":"10.1136\/bmjgh-2018-001114","volume":"4","author":"LT Mazzola","year":"2019","unstructured":"Mazzola, L. T. & Kelly-Cirino, C. Diagnostic tests for Crimean-Congo haemorrhagic fever: A widespread tickborne disease. BMJ Glob. Health 4, e001114 (2019).","journal-title":"BMJ Glob. Health"},{"key":"85323_CR33","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1099\/jgv.0.000610","volume":"97","author":"M Weidmann","year":"2016","unstructured":"Weidmann, M. et al. Biosafety standards for working with Crimean-Congo hemorrhagic fever virus. J. Gen. Virol. 97, 2799\u20132808 (2016).","journal-title":"J. Gen. Virol."},{"key":"85323_CR34","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1128\/JCM.38.3.1144-1150.2000","volume":"38","author":"D Aubert","year":"2000","unstructured":"Aubert, D. et al. Recombinant antigens to detect Toxoplasma gondii-specific immunoglobulin G and immunoglobulin M in human sera by enzyme immunoassay. J. Clin. Microbiol. 38, 1144\u20131150 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"85323_CR35","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0950268800068576","volume":"113","author":"FJ Burt","year":"1994","unstructured":"Burt, F. J., Leman, P. A., Abbott, J. C. & Swanepoel, R. Serodiagnosis of Crimean-Congo haemorrhagic fever. Epidemiol. Infect. 113, 551\u2013562 (1994).","journal-title":"Epidemiol. Infect."},{"key":"85323_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.diagmicrobio.2013.12.015","volume":"79","author":"K Ergunay","year":"2014","unstructured":"Ergunay, K. et al. Antibody responses and viral load in patients with Crimean-Congo hemorrhagic fever: A comprehensive analysis during the early stages of the infection. Diagn. Microbiol. Infect. Dis. 79, 31\u201336 (2014).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"85323_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3201\/eid1804.111374","volume":"18","author":"H Bodur","year":"2012","unstructured":"Bodur, H., Akinci, E., Ascioglu, S., \u00d6ng\u00fcr\u00fc, P. & Uyar, Y. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg. Infect. Dis. 18, 640\u2013642 (2012).","journal-title":"Emerg. Infect. Dis."},{"key":"85323_CR38","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1099\/0022-1317-75-9-2157","volume":"75","author":"AC Marriott","year":"1994","unstructured":"Marriott, A. C., Polyzoni, T., Antoniadis, A. & Nuttall, P. A. Detection of human antibodies to Crimean-Congo haemorrhagic fever virus using expressed viral nucleocapsid protein. J. Gen. Virol. 75, 2157\u20132161 (1994).","journal-title":"J. Gen. Virol."},{"key":"85323_CR39","doi-asserted-by":"publisher","first-page":"e0008364","DOI":"10.1371\/journal.pntd.0008364","volume":"14","author":"B \u00c1lvarez-Rodr\u00edguez","year":"2020","unstructured":"\u00c1lvarez-Rodr\u00edguez, B. et al. Characterization and applications of a Crimean-Congo hemorrhagic fever virus nucleoprotein-specific Affimer: Inhibitory effects in viral replication and development of colorimetric diagnostic tests. PLoS Negl. Trop. Dis. 14, e0008364 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"85323_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ajic.2007.10.007","volume":"35","author":"JD Siegel","year":"2007","unstructured":"Siegel, J. D., Rhinehart, E., Jackson, M., Chiarello, L. & Health Care Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: Preventing transmission of infectious agents in health care settings. Am. J. Infect. Control. 35, 65\u2013164 (2007).","journal-title":"Am. J. Infect. Control."},{"key":"85323_CR41","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1089\/vbz.2011.0896","volume":"12","author":"H Leblebicioglu","year":"2012","unstructured":"Leblebicioglu, H. et al. Case management and supportive treatment for patients with Crimean-Congo Hemorrhagic fever. Vector Borne Zoonot. Dis. 12, 805\u2013811 (2012).","journal-title":"Vector Borne Zoonot. Dis."},{"key":"85323_CR42","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1073\/pnas.0408782102","volume":"102","author":"DH Davies","year":"2005","unstructured":"Davies, D. H. et al. Profiling the humoral immune response to infection by using proteome microarrays: High-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. USA 102, 547\u2013552 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"85323_CR43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s13071-018-2934-1","volume":"11","author":"M D\u00f6\u015fkaya","year":"2018","unstructured":"D\u00f6\u015fkaya, M. et al. Discovery of new Toxoplasma gondii antigenic proteins using a high throughput protein microarray approach screening sera of murine model infected orally with oocysts and tissue cysts. Parasit. Vectors 11, 393 (2018).","journal-title":"Parasit. Vectors"},{"key":"85323_CR44","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.vaccine.2006.10.060","volume":"25","author":"M D\u00f6\u015fkaya","year":"2007","unstructured":"D\u00f6\u015fkaya, M. et al. GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine. Vaccine 25, 1824\u20131837 (2007).","journal-title":"Vaccine"},{"key":"85323_CR45","doi-asserted-by":"publisher","first-page":"e108329","DOI":"10.1371\/journal.pone.0108329","volume":"9","author":"M D\u00f6\u015fkaya","year":"2014","unstructured":"D\u00f6\u015fkaya, M. et al. Diagnostic value of a Rec-ELISA using Toxoplasma gondii recombinant SporoSAG, BAG1, and GRA1 proteins in murine models infected orally with tissue cysts and oocysts. PLoS\u00a0One 9, e108329 (2014).","journal-title":"PLoS\u00a0One"},{"key":"85323_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.trivac.2015.11.002","volume":"5","author":"Y Gedik","year":"2016","unstructured":"Gedik, Y. et al. Immunogenic multistage recombinant protein vaccine confers partial protection against experimental toxoplasmosis mimicking natural infection in murine model. Trials Vaccinol. 5, 15\u201323 (2016).","journal-title":"Trials Vaccinol."},{"key":"85323_CR47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12879-020-05220-2","volume":"20","author":"EA \u015eahar","year":"2020","unstructured":"\u015eahar, E. A. et al. Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis. BMC Infect. Dis. 20, 493 (2020).","journal-title":"BMC Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85323-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85323-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85323-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:24:13Z","timestamp":1670045053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85323-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85323"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85323-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"31 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5936"}}